Company news

PDS Biotechnology Corporation news in 2026

PDS Biotechnology Corporation's news releases, calls and decks from 2026, newest first.

View company

PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors

October 20, 2026

PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases

October 6, 2026

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology

September 22, 2026

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors

September 14, 2026

PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

September 8, 2026

PDS Biotech Reports Second Quarter 2026 Financial Results

August 13, 2026

PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101

August 11, 2026

PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update

May 13, 2026

PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results

May 6, 2026

PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial

April 14, 2026

PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement

March 29, 2026

PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results

March 23, 2026

PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

February 20, 2026

PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

January 28, 2026

PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101

January 22, 2026

PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint

January 9, 2026

Calls in 2026

Decks in 2026